Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin

NCT01994824 is registered in ClinicalTrials.gov with University of Calgary as lead sponsor.

NCT NCT01994824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01994824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin
Lead sponsor
University of Calgary
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2014
Completion date
September 27, 2021
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

graft-vs-host disease